Survival after intensive therapy or clofarabine in fit older adults with acute myeloid leukemia: E2906 phase 3 trial

Blood Neoplasia 2026 Open access

Read full text
Authors: James M. Foran, Zhuoxin Sun, Selina M. Luger, David F. Claxton, Hillard Michael Lazarus, Daniel A. Arber, Jacob M. Rowe, Elisabeth M. Paietta, Janis Racevskis, Francine E. Garrett-Bakelman, Yanming Zhang, Jessica Kaplan Altman
+10 more Aref Al‐Kali, Hong Zheng, Keith William Pratz, E. Randolph Broun, Bayard L. Powell, Kristen Marie O’Dwyer, John E. Godwin, Yishai Ofran, Mark Robert Litzow, Martin S. Tallman
DOI: 10.1016/j.bneo.2026.100194
Cited by: 0
References: 40

Abstract

= .003). In contrast, MRD-positive patients assigned to clofarabine (vs high-dose cytarabine) consolidation had significantly inferior OS. Clofarabine is inferior to standard intensive therapy despite similar remission rates. Achieving MRD-negative remission is associated with high, sustained rates of OS regardless of therapy. Increasing MRD negativity and improving outcomes among MRD-positive patients remain pressing, ongoing challenges. This trial was registered at www.clinicaltrials.gov as NCT02085408.

Fields of Study & Subjects

Acute Myeloid Leukemia Research Retinoids in leukemia and cellular processes Acute Lymphoblastic Leukemia research

Publication details

Journal / source
Blood Neoplasia
Volume
3
Issue
2
Pages
100194–100194
Publication date
14 January 2026
Language
EN